Barclays PLC Increases Position in Greenwich LifeSciences, Inc. (NASDAQ:GLSI)

Barclays PLC increased its stake in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 323.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,560 shares of the company’s stock after buying an additional 6,538 shares during the quarter. Barclays PLC owned about 0.07% of Greenwich LifeSciences worth $123,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. State Street Corp increased its position in Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after acquiring an additional 3,005 shares during the period. Garden State Investment Advisory Services LLC acquired a new position in Greenwich LifeSciences in the 3rd quarter valued at about $253,000. Bank of New York Mellon Corp acquired a new position in Greenwich LifeSciences in the 2nd quarter valued at about $264,000. Finally, Rhumbline Advisers acquired a new position in Greenwich LifeSciences in the 2nd quarter valued at about $117,000. Institutional investors and hedge funds own 4.16% of the company’s stock.

Insider Activity at Greenwich LifeSciences

In other Greenwich LifeSciences news, CEO Snehal Patel acquired 3,200 shares of the stock in a transaction on Monday, December 30th. The shares were bought at an average price of $11.12 per share, with a total value of $35,584.00. Following the acquisition, the chief executive officer now owns 5,539,302 shares of the company’s stock, valued at $61,597,038.24. This trade represents a 0.06 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have purchased 8,000 shares of company stock worth $97,184 in the last quarter. Company insiders own 51.67% of the company’s stock.

Greenwich LifeSciences Stock Down 3.3 %

Shares of GLSI stock opened at $13.35 on Thursday. The stock has a market capitalization of $175.49 million, a PE ratio of -16.69 and a beta of 1.66. Greenwich LifeSciences, Inc. has a 52-week low of $8.00 and a 52-week high of $21.44. The stock’s 50-day moving average price is $13.15 and its 200 day moving average price is $14.13.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.